American Journal of Internal Medicine
Volume 5, Issue 1, January 2017, Pages: 12-17
Received: Jan. 1, 2017;
Accepted: Jan. 20, 2017;
Published: Feb. 20, 2017
Views 4890 Downloads 267
Ahmed A. Obiedallah, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut City, Egypt
Essam Abdelmohsen, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut City, Egypt
Abdalla I. Kelani, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut City, Egypt
Mohamed Mousa, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut City, Egypt
Background: Ascites is the most common complication of liver cirrhosis and about 5-10% of all cases develop refractory ascites, 50% of such patients die within 6 months of its development. Aim of the Work: to assess the usefulness of adding midodrine beside the standard medical treatment for patients with liver cirrhosis and refractory ascites. Patients and Methods: This study included 78 patients with liver cirrhosis and refractory ascites or recurrent ascites, Group A: (n=37) patients on standard medical treatment (SMT) [low sodium diet + diuretic therapy (loop diuretic in a dose 40-160 mg/day and distal acting diuretic in a dose 100-400 mg/day + large volume paracentesis as needed] Group B: (n=41) patients with standard medical treatment (SMT) and midodrine tolerable dose. Results: Statistical significant difference between the SMT group and midodrine group as regard reduction in body weight and increase in mean arterial blood pressure and 24 h-urinary volume where P value was < 0.05. Conclusion, midodrine is a safe treatment for patients with liver cirrhosis and its addition to standard medical treatment is associated with better control of ascites.
Ahmed A. Obiedallah,
Abdalla I. Kelani,
Effect of Midodrine in Patients with Liver Cirrhosis and Refractory Ascites, American Journal of Internal Medicine.
Vol. 5, No. 1,
2017, pp. 12-17.
Sussman AN. and Boyer TD. (2011): Management of Refractory Ascites and Hepatorenal Syndrome. Curr Gastroenterol Rep. 13: 17–25.
Planas R, Montoliu S, Balleste B et al., (2006): Natural history of patients hospitalized for management of cirrhotic ascites. Clin. Gastroenterol. Hepatol. 4: 1385–94.
Salerno F, Cammà C, Enea M, Rِssle M, Wong F. (2007): Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 133: 825–34.
Kashani A, Landaverde C, Medici V, Rossaro L. (2008): Fluid retention in cirrhosis: pathophysiology and management. QJM. F; 101: 71-85.
Cardenas A, Arroyo V. (2003): Mechanism of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab. 17: 607-622.
Runyon BA. (2002): Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH and Fordtran's gastrointestinal and liver disease. Philadelphia: saunders. p. 1517-1542.
Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al., (2000): Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 33: 43–48.
Moreau R, Asselah T, Caudat B, De Kerguenec C, Pessione F, Bernard B, et al., (2002): Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut. 50: 90–94.
Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al., (2002): Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 36: 941–948.
Singh V, Kumar R, Nain CK, Singh B, Sharma AK. (2006): Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized controlled trial. J Gastroenterol Hepatol. 21: 303–307.
Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C, et al., (2008): Prevention of paracentesis-induced circulatory dysfunction: midodrine vs. albumin. A randomized pilot study. Liver Int. 28: 1019–1025.
Krag A, Moller S, Henriksen JH, Niels-Henrik HR, Finn L. (2007): Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 46: 1863–1871.
Kramer, Robert E, Sokol, Ronald J, Baruch Y, Liu, Edwin, MacKenzie, Todd, Hoffenberg, Edward J, Narkewicz, Michael R. (2014): Large-Volume Paracentesis in the Management of Ascites in Children. Journal of Pediatric Gastroenterology & Nutrition. 33: 245-249.
Lin YF, Wang JY, Denq JC, Lin SH. (2003): Midodrine improves chronic hypotension in hemodialysis patients. Am J Med Sci. 325: 256-261.
Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, et al., (2009): The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 29: 169-174.
Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray C JL and Naghavi M. (2014): Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 12: 145.
Sourianarayanane A, Barnes DS, McCullough AG. (2011): Beneficial Effect of Midodrine in Hypotensive Cirrhotic Patients with Refractory Ascites. Gastroenterology & Hepatology. 7; 189-198.39.
Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. (2012): Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. Journal of Hepatology. 56: 348–354.
Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsinos EV. (2007): Effects of a 7 day treatment with midodrine in nonazotemic cirrhotic patients with and without ascites. J Hepatol. 46: 213–221.